288 related articles for article (PubMed ID: 37931487)
1. Indirect impact of the COVID-19 pandemic on the care and outcomes of people with MS: A combined survey and insurance claims study.
Meltzer E; Charron O; Wozny J; Onuorah H; Montague A; Kline AC; Largent A; Krause TM; Freeman L
Mult Scler Relat Disord; 2023 Dec; 80():105085. PubMed ID: 37931487
[TBL] [Abstract][Full Text] [Related]
2. Changes on the health care of people with multiple sclerosis from Latin America during the COVID-19 pandemic.
Chertcoff A; Bauer J; Silva BA; Aldecoa M; Eizaguirre MB; Rodriguez R; Chereque A; Rodríguez Heudebert ML; Milanesi V; Morales L; Castellón M; Mejía Pineda S; Ferrandina F; Henestroza P; Ruiz Peraza M; Vallecillo Rivas F; Cedeño Lopez L; Herrera L; Sosa M; Cruchet Muñoz V; Barahona AS; Ramírez Gudiño LM; Carballido S; Walton C; Peeters LM; Rijke N; Garcea O; Carrá A; Alonso R
Mult Scler Relat Disord; 2021 Sep; 54():103120. PubMed ID: 34243104
[TBL] [Abstract][Full Text] [Related]
3. Multiple sclerosis and COVID-19: Assessing risk perception, patient behaviors and access to disease-modifying therapies.
Beesley R; Cauchi M; Davies L; Upcott M; Norton E; Loveless S; Anderson V; Wynford-Thomas R; Pickersgill TP; Uzochukwu E; Wardle M; Robertson NP; Tallantyre E; Willis MD
Mult Scler Relat Disord; 2022 Dec; 68():104121. PubMed ID: 36088727
[TBL] [Abstract][Full Text] [Related]
4. Use of Telemedicine Among People with Multiple Sclerosis Before and During the COVID-19 Pandemic.
Sumner L; Schmidt H; Minden S; Falkenberg N; Sun L; McBurney R; Loud S; Wallin M
Telemed J E Health; 2023 Aug; 29(8):1152-1163. PubMed ID: 36493358
[No Abstract] [Full Text] [Related]
5. Real-World Clinical and Economic Outcomes Among Persons With Multiple Sclerosis Initiating First- Versus Second- or Later-Line Treatment With Ocrelizumab.
Geiger CK; Sheinson D; To TM; Jones D; Bonine NG
Neurol Ther; 2023 Oct; 12(5):1709-1728. PubMed ID: 37458897
[TBL] [Abstract][Full Text] [Related]
6. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
Iaffaldano P; Lucisano G; Manni A; Paolicelli D; Patti F; Capobianco M; Brescia Morra V; Sola P; Pesci I; Lus G; De Luca G; Lugaresi A; Cavalla P; Montepietra S; Maniscalco GT; Granella F; Ragonese P; Vianello M; Brambilla L; Totaro R; Toscano S; Malucchi S; Petracca M; Moiola L; Ferraro D; Lepore V; Mosconi P; Ponzio M; Tedeschi G; Comi G; Battaglia MA; Filippi M; Amato MP; Trojano M;
Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35046084
[TBL] [Abstract][Full Text] [Related]
7. Impact of the COVID-19 pandemic on the health care of >1,000 People living with multiple sclerosis: A cross-sectional study.
Vogel AC; Schmidt H; Loud S; McBurney R; Mateen FJ
Mult Scler Relat Disord; 2020 Nov; 46():102512. PubMed ID: 32977074
[TBL] [Abstract][Full Text] [Related]
8. Barriers to access and utilization of multiple sclerosis care services in a large cohort of Latin American patients.
Carnero Contentti E; Giachello S; Correale J
Mult Scler; 2021 Jan; 27(1):117-129. PubMed ID: 31961260
[TBL] [Abstract][Full Text] [Related]
9. Electronic health record data for assessing risk of hospitalization for COVID-19: Methodological considerations applied to multiple sclerosis.
Dillon P; Siadimas A; Roumpanis S; Fajardo O; Fitovski K; Jessop N; Whitley L; Muros-Le Rouzic E
Mult Scler Relat Disord; 2023 Mar; 71():104512. PubMed ID: 36716576
[TBL] [Abstract][Full Text] [Related]
10. Impact of adherence to disease modifying therapies on long-term clinical and economic outcomes in multiple sclerosis: A claims analysis of real-world data.
Amezcua L; Livingston T; Hayward B; Zhou J; Williams MJ
Mult Scler Relat Disord; 2023 Sep; 77():104866. PubMed ID: 37487345
[TBL] [Abstract][Full Text] [Related]
11. Healthcare Disruptions and Use of Telehealth Services Among People With Multiple Sclerosis During the COVID-19 Pandemic.
Chen MH; Goverover Y; Botticello A; DeLuca J; Genova HM
Arch Phys Med Rehabil; 2022 Jul; 103(7):1379-1386. PubMed ID: 35093328
[TBL] [Abstract][Full Text] [Related]
12. How the COVID-19 Pandemic has changed multiple sclerosis clinical practice: Results of a nationwide provider survey.
Morrison EH; Michtich K; Hersh CM
Mult Scler Relat Disord; 2021 Jun; 51():102913. PubMed ID: 33839482
[TBL] [Abstract][Full Text] [Related]
13. Trajectories of disease-modifying therapies and associated sickness absence and disability pension among 1923 people with multiple sclerosis in Sweden.
Teni FS; Machado A; Murley C; He A; Fink K; Gyllensten H; Glaser A; Alexanderson K; Hillert J; Friberg E
Mult Scler Relat Disord; 2023 Jan; 69():104456. PubMed ID: 36529068
[TBL] [Abstract][Full Text] [Related]
14. Health care services and disease modifying therapies use in community-based multiple sclerosis patients: Evolution from 2013 to 2015 and demographic characteristics.
Ha-Vinh P; Nauleau S; Clementz M; Régnard P; Sauze L; Clavaud H
Presse Med; 2019 Jan; 48(1 Pt 1):e1-e19. PubMed ID: 30528148
[TBL] [Abstract][Full Text] [Related]
15. A National Representative, Cross-Sectional Study by the Hellenic Academy of NeuroImmunology (HEL.A.NI.) on COVID-19 and Multiple Sclerosis: Overall Impact and Willingness Toward Vaccination.
Boziki M; Styliadis C; Bakirtzis C; Grigoriadou E; Sintila AS; Nikolaidis I; Vrienniou A; Geys L; Pelidou SH; Probert L; Papazisis G; Bamidis P; Grigoriadis N
Front Neurol; 2021; 12():757038. PubMed ID: 34899577
[No Abstract] [Full Text] [Related]
16. A Targeted Literature Search and Phenomenological Review of Perspectives of People with Multiple Sclerosis and Healthcare Professionals of the Immunology of Disease-Modifying Therapies.
Burtchell J; Clemmons D; Clemmons J; Sabutis T; Rosenberg A; Graves J; Sweeney ML; Kramer J; Ziehn M; Brown B; Weiss JL; Obeidat AZ
Neurol Ther; 2022 Sep; 11(3):955-979. PubMed ID: 35608740
[TBL] [Abstract][Full Text] [Related]
17. Patterns of Utilization and Expenditure Across Multiple Sclerosis Disease-Modifying Therapies: A Retrospective Cohort Study Using Claims Data from a Commercially Insured Population in the United States, 2010-2019.
Zhu W; Tang X; Heyman RA; Cai T; Suh K; Seeger JD; Xia Z
Neurol Ther; 2022 Sep; 11(3):1147-1165. PubMed ID: 35598225
[TBL] [Abstract][Full Text] [Related]
18. Frequency and characteristics of falls in people living with and without multiple sclerosis during the COVID-19 pandemic: A cross-sectional online survey.
Zanotto T; Frechette ML; Koziel SR; Hsieh KL; Sosnoff JJ
Mult Scler Relat Disord; 2021 Sep; 54():103111. PubMed ID: 34303279
[TBL] [Abstract][Full Text] [Related]
19. Effect of the COVID-19 pandemic on disease activity in multiple sclerosis patients treated with hematopoietic stem cell transplantation.
Mariottini A; Lotti A; Innocenti C; Repice AM; Nozzoli C; Boncompagni R; Fainardi E; Saccardi R; Massacesi L
Eur J Neurol; 2023 Oct; 30(10):3362-3366. PubMed ID: 37483174
[TBL] [Abstract][Full Text] [Related]
20. Quality of life and mental health in multiple sclerosis patients during the COVID-19 Pandemic.
Rodríguez-Agudelo Y; Nava-Adán J; Paz-Rodríguez F; Abundes-Corona A; Flores-Rivera J; Corona T
Mult Scler Relat Disord; 2023 Feb; 70():104487. PubMed ID: 36640561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
